Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents.

Mu J, Pinkstaff J, Li Z, Skidmore L, Li N, Myler H, Dallas-Yang Q, Putnam AM, Yao J, Bussell S, Wu M, Norman TC, Rodriguez CG, Kimmel B, Metzger JM, Manibusan A, Lee D, Zaller DM, Zhang BB, DiMarchi RD, Berger JP, Axelrod DW.

Diabetes. 2012 Feb;61(2):505-12. doi: 10.2337/db11-0838.

2.

Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody.

Huang J, Ishino T, Chen G, Rolzin P, Osothprarop TF, Retting K, Li L, Jin P, Matin MJ, Huyghe B, Talukdar S, Bradshaw CW, Palanki M, Violand BN, Woodnutt G, Lappe RW, Ogilvie K, Levin N.

J Pharmacol Exp Ther. 2013 Aug;346(2):270-80. doi: 10.1124/jpet.113.204420.

3.

Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice.

Camacho RC, Zafian PT, Achanfuo-Yeboah J, Manibusan A, Berger JP.

Eur J Pharmacol. 2013 Sep 5;715(1-3):41-5. doi: 10.1016/j.ejphar.2013.06.023.

PMID:
23831019
4.

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects.

Xu J, Stanislaus S, Chinookoswong N, Lau YY, Hager T, Patel J, Ge H, Weiszmann J, Lu SC, Graham M, Busby J, Hecht R, Li YS, Li Y, Lindberg R, Véniant MM.

Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1105-14. doi: 10.1152/ajpendo.00348.2009.

5.

A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol.

Huang Z, Wang H, Lu M, Sun C, Wu X, Tan Y, Ye C, Zhu G, Wang X, Cai L, Li X.

PLoS One. 2011;6(6):e20669. doi: 10.1371/journal.pone.0020669.

7.

Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation.

Xu J, Bussiere J, Yie J, Sickmier A, An P, Belouski E, Stanislaus S, Walker KW.

Bioconjug Chem. 2013 Jun 19;24(6):915-25. doi: 10.1021/bc300603k.

PMID:
23594041
8.

Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes.

Hecht R, Li YS, Sun J, Belouski E, Hall M, Hager T, Yie J, Wang W, Winters D, Smith S, Spahr C, Tam LT, Shen Z, Stanislaus S, Chinookoswong N, Lau Y, Sickmier A, Michaels ML, Boone T, Véniant MM, Xu J.

PLoS One. 2012;7(11):e49345. doi: 10.1371/journal.pone.0049345.

9.

A solid-phase PEGylation strategy for protein therapeutics using a potent FGF21 analog.

Song L, Zhu Y, Wang H, Belov AA, Niu J, Shi L, Xie Y, Ye C, Li X, Huang Z.

Biomaterials. 2014 Jun;35(19):5206-15. doi: 10.1016/j.biomaterials.2014.03.023.

PMID:
24685265
10.

Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db/db mice.

Ye X, Qi J, Wu Y, Yu D, Xu P, Li S, Zhu S, Wu Q, Ren G, Li D.

Diabetes Metab. 2015 Feb;41(1):82-90. doi: 10.1016/j.diabet.2014.09.001.

12.

Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1.

Lee SH, Lee S, Youn YS, Na DH, Chae SY, Byun Y, Lee KC.

Bioconjug Chem. 2005 Mar-Apr;16(2):377-82.

PMID:
15769092
13.

Low molecular weight (1 kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice.

Kim TH, Park CW, Kim HY, Chi MH, Lee SK, Song YM, Jiang HH, Lim SM, Youn YS, Lee KC.

Biol Pharm Bull. 2012;35(7):1076-83.

15.

Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity.

Gong N, Ma AN, Zhang LJ, Luo XS, Zhang YH, Xu M, Wang YX.

Br J Pharmacol. 2011 May;163(2):399-412. doi: 10.1111/j.1476-5381.2011.01227.x.

16.

FGF21 suppresses hepatic glucose production through the activation of atypical protein kinase Cι/λ.

Kong LJ, Feng W, Wright M, Chen Y, Dallas-yang Q, Zhou YP, Berger JP.

Eur J Pharmacol. 2013 Feb 28;702(1-3):302-8. doi: 10.1016/j.ejphar.2012.11.065.

PMID:
23305840
17.

Long-lasting hypoglycemic effect of modified FGF-21 analog with polyethylene glycol in type 1 diabetic mice and its systematic toxicity.

Ye X, Qi J, Wu Q, Yu D, Li S, Wu Y, Li D.

Eur J Pharmacol. 2016 Jun 15;781:198-208. doi: 10.1016/j.ejphar.2016.04.025.

PMID:
27089817
18.

Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway.

Chau MD, Gao J, Yang Q, Wu Z, Gromada J.

Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12553-8. doi: 10.1073/pnas.1006962107.

19.

Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21.

Müller TD, Sullivan LM, Habegger K, Yi CX, Kabra D, Grant E, Ottaway N, Krishna R, Holland J, Hembree J, Perez-Tilve D, Pfluger PT, DeGuzman MJ, Siladi ME, Kraynov VS, Axelrod DW, DiMarchi R, Pinkstaff JK, Tschöp MH.

J Pept Sci. 2012 Jun;18(6):383-93. doi: 10.1002/psc.2408.

PMID:
22565812
20.

Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.

Bell SJ, Fam CM, Chlipala EA, Carlson SJ, Lee JI, Rosendahl MS, Doherty DH, Cox GN.

Bioconjug Chem. 2008 Jan;19(1):299-305.

PMID:
18020402

Supplemental Content

Support Center